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Abstract
  
 Senescence is an irreversible cell cycle arrest that inhibit cancer growth and suppress 
the progression of cancer. Some anticancer compounds are known potential to induce 
senescence. Senescence defence against tumour development by preventing proliferation of 
cells with DNA damage. The study aimed to determine the cytotoxic effects and senescence 
induction of Pentagamavunon-0 (PGV-0) on Human Epidermal Growth Factor Receptor 
2-positive (HER2-positive) breast cancer cells, HCC 1954. Cytotoxic tests carried out with 
3- (4.5-dimethylthiazzol-2yl) -2.5-tidiphenyltetrazolium (MTT) assay showed that PGV-0 
exhibited a potent cytotoxic effect with an inhibitory concentration (IC50) value of 39 µM. 
Treatment with PGV-0 at IC50 concentration combined with doxorubicin showed cytotoxic 
enhancement effects. The senescence assay using SA-β-Galactosidase assay showed that the 
PGV-0 alone induced senescence with a percentage of cell senescent of 15%. The combination 
treatment of PGV-0 at the half dose of IC50 with doxorubicin 100 nM was able to induce 
senescence with the percentage of senescent cells of 25%. Moreover, PGV-0 also increased 
intracellular reactive oxygen species (ROS). The results of this study indicate that PGV-0 
exhibits cytotoxic effect, increases cytotoxic effect of doxorubicin and induces senescence 
that may correlate to the increasing of intracellular ROS in HCC 1954 cells.
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INTRODUCTION
 Human epidermal growth factor receptor 2 
(HER2) is highly expressed in approximately 20-
30% of breast cancers and associated with more 
aggressive diseases, higher recurrence rates, and 
shorter survival (Dawood, et al., 2010; Slamon, 
et al., 1989). Several drugs targeted on this recep-
tor are introduced and has been clinically used but 
become resistance due to the alteration of HER2 
expression or mutations (Dawood, et al., 2010). 
Therefore, the development of agents in this regard-
ing target are still a challenge to obtain the more 
broad spectrum for HER2 alteration with the ad-
ditional of metabolic targets.  In this concern, it is 
important to find the anti-cancer agent that kill the 
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cancer cells through apoptosis in correlation with 
senescence evidence. 
 Senescence is a complex stress response 
when cells lose the capacity to proliferate irre-
versibly, followed by various changes in gene ex-
pression (Campisi, 2013). The role of senescence 
in cancer treatment includes senescent cells that 
have lost the ability to undergo cell division perma-
nently, even though they may be fully metabolically 
active, therefore can suppress and reduce cancer 
growth (Campisi, 1997). Treatment of lapatinib in 
HER2-positive cell line induces senescence with 
accumulation of SA-β-Galactosidase (McDermott, 
et al., 2019). Previous studies treatment using dox-
orubicin low-dose in colorectal cancer cells induce 
senescence rather than apoptosis (Sliwinska, et 
al., 2009). Cells that cannot induce apoptosis, se-
nescence can act as a ‘backup’ response and con-
tribute to treatment outcomes (Huun, et al., 2017). 
Collectively, senescence plays an important role in 
inhibiting cancer growth and contribute to cancer 
therapy.
 Molecular national team, Faculty of Phar-
macy, Universitas Gadjah Mada developed cur-
cumin analogues, namely Pentagamavunon-0 
(PGV-0) and Pentagamavunon-1 (PGV-1) that has 
been investigated by Cancer Chemoprevention 
Research Center (CCRC), Faculty of Pharmacy, 
Universitas Gadjah Mada of their potential for an-
ticancer. Beside that, CCRC also developed many 
anticancer compounds from natural materials and 
synthetic compounds. The synthetic compounds 
such as Pentagamaboronon-0 (PGB-0) and Pentag-
amaboronon-0 complex (PGB-0) with fructose and 
sorbitol exhibited anticancer properties. PGB-0 re-
ported to decreased the viability of MCF-7/HER2 
cells (Utomo, et al., 2017) and 4T1 cells (Kusumas-
tuti, et al., 2019). The PGB-0 in a complex form with 
sorbitol (PGB-0-So) increased cytotoxicity against 
MCF-7/HER2 cells (Qodria, et al., 2018). Whereas, 
PGV-0 is known to have cytotoxic activities in var-
ious types of cancer cells, including breast cancer 
(Hermawan, et al., 2011). Molecular docking stud-
ies revealed that PGV-0 can interact with several 
proteins including HER2 protein (Meiyanto, et al., 
2014). This interaction can be directly compared to 
ATP and lapatinib, a chemotherapeutic agent specif-
ically targeted on HER2. However, in some cancer 
cells, the cytotoxic property of PGV-0 is still infe-
rior compared to PGV-1, the other curcumin analog 
(Meiyanto, et al., 2019, 2018). This data suggests 
that the PGV-0 potential to be further developed as 
a specific target of co-chemotherapeutic agent for 
HER2-positive breast cancer.
 Moreover, PGV-0 induced apoptosis and 
cause cell cycle arrest on MCF-7 breast cancer cells 
(Hermawan, et al., 2011; Meiyanto, 2011). In ad-
dition to the potential for single cytotoxicity of the 
PGV-0, PGV-0 can increase the cytotoxic effects of 
doxorubicin and have the potential as a co-chemo-
therapy agent. PGV-0 increases cytotoxic effect of 
doxorubicin through suppressed HER2 and P-gp 
expression which leads to the induction of apopto-
sis (Meiyanto, et al., 2014). Hence, we explore the 
potential of PGV-0 in inhibition of proliferation, 
and mechanism of action through senescence in 
HER2-positive HCC1954 breast cancer cells.
METHODS
Cell Culture
 HCC 1954 breast cancer cell line was kindly 
obtained from Dr. Muhammad Hasan Bashari, Uni-
versitas Padjadjaran, Indonesia. Cell cultures were 
grown with the Roswell Park Memorial Institute 
(RPMI, New York, USA) with 10% Fetal Bovine 
Serum (Sigma-Aldrich, St. Louis, USA), penicil-
lin-streptomycin 1% v⁄v (Gibco, New York, USA) . 
Cells were incubated at 37oC at 5% CO2. Curcumin 
and PGV-0 were obtained from the Curcumin Re-
search Center (CRC), Faculty of Pharmacy, Univer-
sitas Gadjah Mada and doxorubicin  was purchased 
from Wako, Japan.
Cytotoxic Test
 Cytotoxicity tests were carried out using the 
MTT (3- (4.5-dimethylthiazzol-2yl) -2.5-tidiphe-
nyltetrazolium) assay refered to (Mosmann, 1983) 
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with modification. Briefly, a 96-well microplate was 
seeded with 1954 HCC cells in the amount of 8x103 
cells in 100 μL per well and incubated for 24 h. The 
next day, cells were treated with curcumin and PGV-
0 and the combination with doxorubicin at various 
concentrations and incubated for 24 h at 37oC with 
5% CO2. Then, 100 μL 0.5 mg/mL of MTT reagent 
(Biovision, California, USA) was added and cells 
were incubated for 2 h. The reaction was stopped by 
adding an SDS stopper solution containing 0.01N 
HCl and incubated overnight. Absorbance was then 
measured using a plate reader (BioRad, California, 
USA) at 595 nm.
Senescence-associated β-Galactosidase 
assay (SA-β-Galactosidase assay)
 SA-β-Galactosidase assay was carried out 
using X-Gal staining as previously reposted (Lara-
sati, et al., 2018). In brief, HCC 1954 cells (2x105 
cells/well) were seeded on 6 well plates, incubated 
for 24 h. After that, the cells were treated with cur-
cumin and PGV-0 and the combination  of PGV-0 
with doxorubicin at various concentrations and in-
cubated for 24 h at 37oC with 5% CO2. Then cell fix-
ation was performed with fixation buffer (4% para-
formaldehyde, glutaraldehyde and aquabidest), 10 
minutes incubation. Then added 2mL X-Gal solu-
tion containing X-Gal (Sigma-Aldrich, St. Louis, 
USA), K3Fe [CN]6, K4Fe [CN]4, MgCl2, PBS2X and 
Aquabidest. The plate was incubated in a non CO2 
incubator at 37oC. Then cells were observed after 
24, 48 and 72 h staining with an inverted micro-
scope (Olympus CKX41) (Debacq-Chainiaux, et 
al., 2009). Further analyzed using ImageJ 1.51j8 
java 1.8.0_112 and IBM SPSS Statistics program. 
Intracellular Reactive Oxygen Species (ROS) 
Level with Flowcytometry
 HCC 1954 cells was cultured with 2x104 
in culture media (RPMI) and incubated for 24 h 
at 37oC. Cultured media was removed and washed 
1x PBS once. Cells were treated with PGV-0 30 
μM, doxorubicin 100 nM and both. Cells were 
stained using the 2’,7’–dichlorofluorescin diacetate 
(DCFDA) Staining Kit (BD Bioscience, San Jose, 
California) according to the manufacturer’s instruc-
tions, and analyzed with a FACSCalibur flow cy-
tometer (BD Bioscience, San Jose, California).
RESULTS
PGV-0 Shows Cytotoxicity on HCC 1954 Cell 
Line
 The purpose of this research was to find out 
the cytotoxic potential of PGV-0 as chemopreven-
tive agent and the combined effects with doxoru-
bicin. First, we evaluated the cytotoxic activity of 
the PGV-0 and compared it with Curcumin on HCC 
1954 cells. The result showed that the treatment of 
PGV-0 and curcumin at the concentration of 5-100 
μM exhibited a cytotoxic effect on HCC 1954 cells 
in a dose-dependent manner with IC50 value of 39 
μM and 36 μM respectively (Figure 1A). Whereas 
the Cytotoxic effect on Vero cells showed the IC50 
value of 235 μM and 74 μM respectively. Curcumin 
more toxic than PGV-0 on Vero cells. The selec-
tivity of PGV-0 against normal vero cells (Figure 
1B) compared to HCC 1954 cells, with selectivity 
index value of 6.02. This value reached the mini-
mum selective number which is 3, so that the PGV-
0 is selective for normal cells. Decreasing viability 
of HCC 1954 cells after PGV-0 treatment can be 
seen from changes in cells morphology after 24 h 
of treatment compared to the untreated group (cell 
control) (Figure 1C). 
PGV-0 Increases Cytotoxicity of  Doxorubicin
 PGV-0 and curcumin exhibited a weak 
cytotoxic effect on HCC 1954 cells, yet this phe-
nomena still potential to be studied further as dox-
orubicin co-chemotherapeutic agent. The results of 
cytotoxic combinations of PGV-0 with doxorubicin 
on HCC 1954 cells (Figure 2A) showed that the 
combination of sub-doses of PGV-0 (1/2, 1/4 and 
1/8 IC50) with doxorubicin 100, 300, 600 nM had 
CI values of <1 (Figure 2B). These CI values show 
synergistic effect between PGV-0 and doxorubicin. 
The most synergistic combination of the sub-dose 
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concentration treatment was 1/2 IC50 PGV-0 with 
doxorubicin 600 nM. The combination of the low-
est concentration of sub-dose 1/8 IC50 with Dox-
orubicin 100 nM showed a synergistic effect and 
increased the cytotoxic effect of doxorubicin.
PGV-0 Induced Senescence
 To determine the mechanism of prolifer-
ation inhibition, we evaluated the induction of se-
nescence on HCC 1954 cells following single dose 
treatment of IC50 1/2 and 1/4 IC50 treatment. Also, 
we tested the effect of the combination of PGV-0 
with doxorubicin on induction of senescence. Se-
nescent cell were characterized by the green col-
oration of cells by X-gal dyes. This indicates the 
accumulation of β-galactosidase in senescent 
cells. Green colour formed in the cells identified 
as senescent positive cells (Figure 3B). The re-
sults showed that the sub-dose concentration 1/2 
IC50 of PGV-0 increased senescent positive cells 
higher than that of the untreated group (Figure 3A). 
The senescent cell treatment with 1/2 IC50 and 1/4 
IC50 PGV-0 sub-dose increased by 16% and 15% 
compared to the untreated group. Combination 
treatment PGV-0 1/2 and 1/4 IC50 with doxoru-
bicin 100 nM increased senescent positive cells by 
25% and 18% compared to doxorubicin 100 nM.
PGV-0 Increases Intracellular Reactive Oxy-
gen Species (ROS) Levels
 To determine the mechanism of further in-
duction senescence and inhibit proliferation cells, 
we evaluated intracellular reactive oxygen species 
levels in HCC 1954 cells. This result showed that 
treatment with PGV-0 30 μM significantly increased 
0.2 fold mean fluorescence intensity compared with 
untreated. Combination treatment PGV-0 30 μM 
with Doxorubicin 100 nM significantly increases 
ROS levels compared treatment with doxorubicin 
100 nM. PGV-0 and combination with doxorubicin 
increases intracellular ROS in HCC 1954 cells.
Figure 1. Cytotoxic effect of Pentagamavunon-0 (PGV-0) on HCC 1954 cells. Cytotoxic profile of Curcumin and 
PGV-0 on HCC1954 cells describing correlation between concentration and cell viability (A) Curcumin and PGV-0 
performed cytotoxic effect with IC50 value of 36 μM and 39 μM. Cytotoxic profile of PGV-0 on HCC1954 and Vero 
cells (B). The cell morphology after treatment with PGV-0 in various concentrations and scale bar 100 μM (C), 
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Figure 2. Cytotoxic effect of Combination Pentagamavunon-0 (PGV-0) and Doxorubicin on HCC 
1954 cells (A) and Combination Index (CI) value (B). A Cytotoxic profile of Combination of PGV-
0 and doxorubicin with various Concentration on HCC1954 cells describing correlation between con-
centration and cell viability. PGV-0 performed cytotoxic effect with combination index (CI)<1. 
Figure 3. Senescence induction of Single and Combination Treatment Pentagamavunon-0 (PGV-0) on 
HCC 1954 cells (A) Quantification of cell senescent precentage on each treatment at 24 h. Statis-
tical analysis of % senescent cell on single treatment at 24 h (*p<0.05) by ANOVA one way test com-
pared to untreated cells and combination treatment compared to doxorubicin. PGV-0 induced sen-
scence on HCC 1954 at 8 μM and 15 μM concentration either in single or combination with 100 
nM Doxorubicin at 24 h. (B) Red arrows show accumulation of SA-β-Galactosidase on the cells.
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DISCUSSION
 
 Curcumin and Curcumin Analog, PGV-0, 
have been known to possess cytotoxic or antipro-
liferative effects on several cancer cell lines such 
as MCF-7, T47D, HeLa, Raji, Myeloma and WiDr 
(Hermawan, et al., 2011; Ikawati and Septisetyani, 
2018; Meiyanto, 2011). Exploration of curcumin 
and its analogues as co-chemotherapeutic agents 
provides new insight for reducing chemoresis-
tance and side effects toxicity toward normal cells. 
Results of this study showed that the PGV-0 per-
formed cytotoxic effect in HCC 1954 cells, a cell 
model of HER2 positive cancer cells. Cytotoxic 
effect of curcumin and PGV-0 are almost similar, 
with the IC50 values of 36 μM and 39 μM, respec-
tively. These IC50 values indicated that both com-
pounds are categorized to be weak cytotoxic effects. 
However based on the selectivity index, those com-
pounds could be developed as adjuvant therapy for 
metastatic cancer or co-chemotherapeutic agents.
 Curcumin deserves a special mention 
among the list of adjuvants due to its better success 
rate in cancer chemotherapy (Sa and Das, 2008). 
Curcumin is a nontoxic agent toward normal cells 
and has been proposed to increase the therapeutic 
efficiency of chemotherapeutics. Curcumin and 
its analogues PGV-0 in combination with doxo-
rubicin increases the sensitivity of MCF-7 cells 
that are resistant to doxorubicin (Meiyanto, et al., 
2014). This study demonstrated that the combina-
tion of PGV-0 with doxorubicin increased cyto-
toxic effect synergistically. Results of this study 
supported the previous studies which showed that 
PGV-0 increased cytotoxic doxorubicin in MCF-
7 cells, and also declare the potential of PGV-0 
as a co-chemotherapeutic agents of doxorubicin.
 Moreover we found that both PGV-0 and 
curcumin alone and combination induced senes-
cence in correlation with their cytotoxic activities. 
PGV-0 is potential to be further developed as a 
specific target of co-chemotherapy agents for pos-
itive HER2 breast cancer. It was discovered that 
curcumin arrested cells in the G2/M phase and in-
duces apoptosis and senescence (Larasati, et al., 
2018). In this regard, curcumin binds to several 
enzymes that function in the metabolic pathways 
of ROS and regulate levels of intracellular ROS, 
which trigger the checkpoints that are dependent 
on p53, resulting in apoptosis or aging (Larasati, et 
Figure 4. PGV-0 increases intracellular ROS levels to inhibit HCC 1954 cell proliferation. Cells (2× 105 cells/mL) were 
treated with PGV-0 (30 μM), Doxorubicin 100 nM and both for 24 h, and subjected to the ROS detection analysis 
using FACS. Results are the average of three independent experiments (means ± SD).
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al., 2018). The increasing ROS under PGV-0 treat-
ment suggested the marked point of its cytotoxic 
property. PGV-0 might induced senescence through 
targets that with curcumin which are ROS metab-
olizing enzymes. However the cytotoxic effect in 
this HER2 positive cells may be also correlated to 
its affinity to bind and inhibit HER2. All of these 
possibilities are subjected to be explored further.
CONCLUSION
 
 PGV-0 exhibits cytotoxic effect, increases 
cytotoxic effect of doxorubicin and induces se-
nescence in HCC 1954 cells. PGV-0 is potential 
to be developed as a co-chemotherapeutic agent.
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